https://www.bioworld.com/rss en-us Derm-Biome Pharmaceuticals Inc. has released promising preclinical results for its novel small molecule, DB-006, demonstrating efficacy in treating atopic dermatitis. http://www.bioworld.com/articles/732027 Fri, 19 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732027-derm-biomes-db-006-shows-efficacy-in-atopic-dermatitis-model 3D illustration of the cross-section of skin layers with atopic dermatitis Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib (TAK-279) demonstrated statistical superiority over Bristol Myers Squibb Co.’s first-in-class Sotyktu (deucravacitinib) in a top-line phase III Latitude Atlas readout of moderate to severe plaque psoriasis. http://www.bioworld.com/articles/731981 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731981-takedas-zasocitinib-bests-sotyktu-in-phase-iii-psoriasis-trial Dermatology exam Avalo Therapeutics Inc. is advancing AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody with potential for hidradenitis suppurativa and additional inflammatory disorders http://www.bioworld.com/articles/731960 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731960-avalo-therapeutics-advances-avtx-010-for-hidradenitis-suppurativa Monoclonal antibody illustration Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib (TAK-279) demonstrated statistical superiority over Bristol Myers Squibb Co.’s first-in-class Sotyktu (deucravacitinib) in a top-line phase III Latitude Atlas readout of moderate to severe plaque psoriasis. http://www.bioworld.com/articles/731816 Fri, 12 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731816-takedas-zasocitinib-bests-sotyktu-in-phase-iii-psoriasis-trial Dermatology exam Dermasensor Inc. received CE mark approval for its handheld skin cancer detection device using spectroscopy and AI to test suspicious skin lesions for cancer in real time at the point of care. The device is designed to help qualified healthcare professionals decide whether suspicious skin lesions need further investigation. With skin cancer rates rising, the Dermasensor joins several other AI-based tools entering the European market to help with the analysis of suspicious lesions. http://www.bioworld.com/articles/731800 Thu, 11 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731800-dermasensor-receives-ce-mark-for-skin-cancer-detection-device Dermasensor device Dermasensor's skin cancer detection device. Credit: Dermasensor Inc. Kymera Therapeutics has developed KT-579, a potent and selective IRF5 degrader as a novel approach for treating systemic lupus erythematosus (SLE) and Sjögren disease. http://www.bioworld.com/articles/731761 Tue, 09 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731761-kymeras-kt-579-shows-promise-for-sle-treatment Illustration of B cell releasing antibodies Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by dysregulation in humoral immunity and sustained activation of B cells and autoantibody release, where BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) play crucial roles in B-cell differentiation and survival. Genescience Pharmaceutical Co. Ltd. has released data for its dual BAFF and APRIL inhibitor Gensci-136 for the treatment of SLE. http://www.bioworld.com/articles/731740 Mon, 08 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731740-genescience-presents-data-on-gensci-136-a-dual-baff-april-inhibitor-for-sle B-cell releasing antibodies Turn Therapeutics Inc. made public strongly positive findings from an interim analysis that involves the first 50 subjects in the ongoing phase II atopic dermatitis (AD) trial with IL-36 inhibitor GX-03. http://www.bioworld.com/articles/731511 Mon, 01 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731511-phase-ii-bid-turns-out-safe-easi-effective-ad-topical-island Hand holding elbow Apogee Therapeutics Inc. loaded up on what could total as much as $1.3 billion in financial fuel from Blackstone Life Sciences funds that will be used to propel zumilokibart (zumi), which yielded positive phase II results in atopic dermatitis (AD). A phase III experiment with the anti-IL-13 antibody is planned for the second half of this year, pending talks with regulators. http://www.bioworld.com/articles/731418 Wed, 27 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731418-apogee-orbiting-big-ad-market-as-apex-phase-ii-data-land Close up dermatitis on the skin Cell therapy based on fibroblasts has shown promise in the treatment of psoriasis due to immune modulation capability and strong expansion when cultured. Work at Fibrobiologics Inc. has focused on the impact of culture format and donors of human dermal fibroblasts (HDFs) on the therapeutic efficacy and immune responses in murine models of psoriasis. http://www.bioworld.com/articles/731294 Wed, 27 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731294-cyps-317-exerts-durable-immunomodulation-in-psoriasis Skin irritation on hands Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases. http://www.bioworld.com/articles/731235 Thu, 21 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731235-recludix-presents-stat1-3-inhibitors-for-dermatological-diseases Skin irritation on hands Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation. GenSciP166 was assayed in vitro as well as in vivo in the MC903 atopic dermatitis murine model. http://www.bioworld.com/articles/731177 Wed, 20 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731177-genescience-presents-stat6-degrader-for-atopic-dermatitis Netherton syndrome is a rare disease caused by loss of activity of the lympho-epithelial Kazal-type-related inhibitor (LEKTI) protein, which in turn is caused by mutations in its encoding gene, SPINK5. This deficiency leads to the triggering of the kallikrein (KLK) signaling cascade resulting in skin barrier dysfunction, inflammation and atopy. At the recent Society for Investigative Dermatology meeting, Biocryst Pharmaceuticals Inc. presented early data on BCX-17725, a KLK5/KLK14 inhibitor fusion protein developed to restore LEKTI functioning in patients with Netherton syndrome. http://www.bioworld.com/articles/731160 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731160-biocrysts-bcx-17725-as-new-approach-for-netherton-syndrome Skin anatomy and DNA Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of atopic dermatitis (AD). Targeting STAT6, the key downstream mediator, offers a more selective strategy that could reproduce biologic efficacy while reducing off-target effects. http://www.bioworld.com/articles/731157 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731157-recludixs-first-in-class-stat6-inhibitor-shows-efficacy-in-atopic-dermatitis Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry into the cell. This is the first time that antibodies have been shown to bind effectively to two essential viral proteins, creating a dual blockade that prevents infection. Unlike the current vaccine, which is based on an attenuated virus and is not recommended for immunocompromised individuals, these monoclonal antibodies could be used both as a new vaccine approach and as a treatment for the entire population. http://www.bioworld.com/articles/730929 Thu, 07 May 2026 11:00:00 -0400 https://www.bioworld.com/articles/730929-first-measles-treatment-advances-as-vaccination-rates-drop Rendering of a key measles protein targeted by neutralizing human antibodies This rendering shows a key measles protein (white) targeted by neutralizing human antibodies (pink). Credit: Dawid Zyla, La Jolla Institute for Immunology Avalo Therapeutics Inc. may have designed in lead asset abdakibart, a drug for hidradenitis suppurativa (HS) that offers a novel mechanism of action, wide dosing interval, and more-than-satisfying outcomes on the Hidradenitis Suppurativa Clinical Response 75 endpoint, just what the doctor – and Wall Street – ordered. http://www.bioworld.com/articles/730861 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730861-abdakibart-phase-ii-graded-puts-avalo-in-hs-upper-class Hand held near armpit Evotec SE has announced the nomination of a small-molecule preclinical development candidate from its multi-target drug discovery alliance in medical dermatology with Almirall SA. The program is aimed at developing novel treatments for immune-mediated inflammatory skin diseases with high unmet medical need. The collaboration, established in 2022, leverages Evotec’s fully integrated, AI/machine learning enhanced discovery and preclinical development platforms. http://www.bioworld.com/articles/730882 Tue, 05 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730882-evotec-and-almirall-derm-alliance-yields-development-candidate Illustration showing skin anatomy BLR Bio LLC has presented new data highlighting the potential of BLR-200 for the treatment of systemic sclerosis (scleroderma). The company also presented data on its research on CCN proteins as potential noninvasive biomarkers for systemic sclerosis. http://www.bioworld.com/articles/730813 Mon, 04 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730813-blr-bios-blr-200-shows-promise-in-systemic-sclerosis-models Photo of older woman holding hand that's colored red Dermatology specialist Leo Pharma A/S is moving into gene therapy with the $50 million acquisition of Replay Holdings LLC, a seed-stage company that is developing high capacity herpes simplex virus vectors to treat rare inherited diseases. http://www.bioworld.com/articles/730748 Thu, 30 Apr 2026 11:00:00 -0400 https://www.bioworld.com/articles/730748-dermatology-specialist-leo-pharma-makes-a-50m-move-into-gene-therapy Skin anatomy and DNA Pharmability AB (formerly Tirmed Pharma AB) has completed its GLP toxicology program for TIR-C, the company’s cutaneous drug candidate for atopic dermatitis, confirming a favorable safety profile. http://www.bioworld.com/articles/730796 Thu, 30 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730796-pharmability-completes-toxicology-program-for-tir-c In its largest acquisition to date, Chiesi Group is buying Kalvista Pharmaceuticals Inc. for $27 per share, a roughly 40% premium to the previous day’s closing price, putting the total deal value at about $1.9 billion. In return, the Italian pharma firm adds to its rare disease franchise Kalvista’s recently approved hereditary angioedema (HAE) drug, plasma kallikrein inhibitor Ekterly (sebetralstat), which has gotten off to a strong commercial launch as the only orally available, on-demand treatment for HAE. http://www.bioworld.com/articles/730681 Wed, 29 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730681-chiesi-snags-on-demand-hae-drug-in-19b-kalvista-buy Ekterly pill and packaging Credit: Kalvista Pharmaceuticals Inc. Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc. http://www.bioworld.com/articles/730787 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b Three red darts on target Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc. http://www.bioworld.com/articles/730643 Mon, 27 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730643-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b Three red darts on target Shares of Veradermics Inc. spiked as the first top-line readout from its registrational program for VDPHL-01 showed the oral, extended-release version of minoxidil surpassed expectations in men with mild to moderate pattern hair loss, setting up commercial aspirations as a potential best-in-indication treatment option. http://www.bioworld.com/articles/730639 Mon, 27 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730639-mane-event-veradermics-beats-expectations-in-pattern-hair-loss-trial Male hair loss As Sanofi SA gets ready to welcome a new CEO, the company along with partner Regeneron Pharmaceuticals Inc. said a happy hello as well to robust sales of Dupixent (dupilumab, dupi) and gained U.S. FDA clearance for the IL-4 receptor alpha antagonist to treat children, ages 2 to 11, with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihistamine treatment. http://www.bioworld.com/articles/730601 Thu, 23 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730601-dupi-whoopie-sanofi-regeneron-cheered-for-sales-new-approval Dupixent Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on oncology. http://www.bioworld.com/articles/730574 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730574-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b Two arrows in opposite directions With rezpegaldesleukin (rezpeg) phase IIb data in alopecia areata holding strong over time, backers of Nektar Therapeutics Inc. are hopeful that the biologic can do for the hair loss market what Dupixent (dupilumab, Regeneron Pharmaceuticals Inc./Sanofi SA) did in atopic dermatitis. http://www.bioworld.com/articles/730481 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730481-nektars-rezpeg-more-than-worth-its-salt-in-alopecia-phase-iib Hand showing bald patch of scalp Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on oncology. http://www.bioworld.com/articles/730407 Fri, 17 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730407-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b Two arrows in opposite directions If a recent warning letter is anything to go by, the U.S. FDA could be using the 2013 Drug Supply Chain Security Act as another enforcement tool to shut down unauthorized suppliers by clamping down on the dispensers that purchase their unapproved drug products. http://www.bioworld.com/articles/730300 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730300-us-fda-cites-first-dispenser-for-violating-rx-supply-chain-act FDA sign Abbvie Inc. is buying exclusive rights to develop, manufacture and commercialize two Nav1.8 inhibitors for pain – HSK-55718 and HSK-51155 – from Haisco Pharmaceutical Group Co. Ltd. for $30 million up front and up to $715 million in milestone payments, plus royalties. http://www.bioworld.com/articles/730297 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730297-abbvie-nabs-two-nav18-pain-projects-from-haisco-in-745m-deal Open capsule delivering pain relief to body